Rallybio Corporation (RLYB)

The immediate catalyst driving Rallybio is the announced merger with Candid Therapeutics, which has sparked a dramatic price recovery from multi-year lows. This corporate restructuring provides a temporary narrative of survival and potential value creation, justifying a neutral-to-slightly-bearish short-term stance rather than a full sell, as the stock is trading near its 52-week low relative to the recent surge. However, the long-term investment case is severely compromised by a catastrophic multi-year decline; the company has lost nearly 95% of its value over the last three years, with every single year showing double-digit percentage losses. This relentless downward trajectory, combined with negative operating margins, massive free cash outflows, and a forward P/E that implies continued losses, signals a business in deep distress where the market has priced out any hope of sustainable operations without the merger. Furthermore, there is no dividend support whatsoever, offering no income buffer against the equity erosion. While the merger offers a lifeline, the underlying fundamentals remain broken, making this a high-risk speculative play rather than a viable long-term holding.